skip to main content
UK Health Security Agency

DLKP-A

DLKP-A

Catalogue No.

20082607

Cell Line Name

DLKP-A

Cell Line Description

DLKP-A is a 300-fold Adriamycin resistant variant of a poorly differentiated squamous cell carcinoma isolated from a lymph node metastases of lung carcinoma from a 52 year old male. DLKP (ECACC Acc. 20082601) (the parent line) was established from a patient that smoked approximately 40 cigarettes a day for most of his adult life.

DLKP displays chromosomal deletions and rearrangements (translocations and isochromosomes) and DLKP-A displays a higher frequency of double minute chromosomes than the parent.

Cells have a doubling time of about 20 hrs. Different levels of cross-resistance were observed towards VP-16, VM-26, colchicine, vincristine and, somewhat unexpectedly, cis-platin. Resistance was stable for at least 3 months in culture in the absence of drug. The adapted cells were designated by an "A" after the name of the cell line, with DLKP-A cells adapting very quickly.

Characteristics

Receptors

Expresses PGP (P-glycoprotein)

Products

DNA fingerprinting (Depositor testing) confirmed DLKP-A as derived from DLKP. Confirmed by STR analysis at ECACC. Variant of DLKP isolated by exposure to increasing concentrations of Adriamycin (2.45 μg/ml). 380-fold resistance to Adriamycin compared to parent (24.8 nM). Cross resistance to Vincristine (2587-fold to parent (1.2nM)) and VP16 (79-fold resistant to parent (146 nM)).

Tissue of Origin

Poorly differentiated lung carcinoma, established from a lymph node biopsy.

Morphology

Epithelial

DNA profile (STR Profile)

Amelogenin: X, Y
CSF1PO: 12, 12
D3S1358: 17, 17
D5S818: 10, 11
D7S820: 8, 11
D8S1179: 13, 14
D13S317: 12, 12
D16S539: 10, 12
D18S51: 13, 13
FGA: 20, 20
Penta D: 11, 11
Penta E: 7, 15
TH01: 9.3, 9.3
TPOX: 8, 11
vWA: 17, 17

Karyotype

Parental DLKP displays chromosomal deletions and rearrangements (translocations and isochromosomes) and DLKP-A displays a higher frequency of double minute chromosomes than the parent.

Applications

Adriamycin-resistant variant of DLKP used in drug resistance studies.

Disease

Lung squamous cell carcinoma

Culture Conditions

Cell Type

Poorly differentiated squamous

Subculture Routine

Upon resuscitation count cells and seed at the higher end of the seeding density to establish culture. Feed with fresh growth medium the following day.

Seed cells between 1-4 x 104 cells/cm2.

8% CO2 at 37°C (as medium is a mixture of DMEM/Ham's F12). Trypsinise using Trypsin/EDTA.

Culture Medium

DMEM:Ham's F-12 (1:1) + 5% Foetal Bovine Serum (FBS) + 2mM L-Glutamine

Adriamycin at a final concentration of 2.45 µg/ml

Freeze in 5% DMSO + 45% FBS + 50% growth medium.

Growth Mode

Adherent

Additional Info

Depositor

Martin Clynes, National Institute for Cellular Biotechnology, Dublin City University. Originator: Geraldine Grant (1989): National Institute for Cellular Biotechnology (formerly National Cell and Tissue Culture Centre), Dublin City University.

Country of Origin

Ireland

GMO Status

Not Applicable

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Clynes M, Redmond A, Moran E, Gilvarry U. Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A. Cytotechnology. 1992;10(1):75–89. doi:10.1007/bf00376102 PMID:1369413

Bibliography

Heenan M, Kavanagh K, Redmond A, et al. (1996). Cytotechnology. 19(3): pp237–242. doi:10.1007/bf00744218

 

Heenan M, O'Driscoll L, Cleary I, Connolly L, Clynes M. (1997). Int J Cancer: 71(5): pp907–915.

 

Toner AP, McLaughlin F, Giles FJ, et al. (2013). Br J Cancer.109(8): pp2131-2141. doi:10.1038/bjc.2013.537

 

Keenan J, Murphy L, Henry M, Meleady P, Clynes M. (2009) Proteomics 9: pp 1556–1566.

 

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: DLKP-A (ECACC 20082607).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

 

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.